166Ho放射性栓塞治疗结直肠癌的剂量-效应关系
本研究分析HEPAR II和SIM研究中接受166Ho放射性栓塞的40例不可手术、化疗难治性结直肠癌肝转移患者,利用治疗后166Ho SPECT/CT估算吸收剂量,18F-FDG PET/CT评估代谢反应。发现肿瘤吸收剂量与反应相关,平均肿瘤吸收剂量超过90 Gy者生存显著优于低于90 Gy者(HR 0.16),且毒性随肝实质吸收剂量增加而增加。
要点
- 平均肿瘤吸收剂量超过90 Gy者生存显著优于低于90 Gy者(HR 0.16,95%CI 0.06-0.511)。
- 完全或部分缓解者的平均肿瘤吸收剂量较进展者高84%(95%CI 20%-180%)。
- 临床毒性CTCAE等级每增加一级,肝实质吸收剂量平均差异为5.75 Gy(95%CI 1.18-10.32)。
核心结论
- 在结直肠癌166Ho放射性栓塞患者中建立了显著的剂量-反应关系,并发现毒性反应与肝实质剂量呈正相关。
- 作者主张未来使用166Ho侦察剂量选择患者并个体化给药活度,目标为平均肿瘤吸收剂量超过90 Gy且肝实质剂量低于55 Gy。
研究设计与样本
- 分析HEPAR II和SIM研究中接受166Ho放射性栓塞的结直肠癌患者。
- 共纳入40例患者。
- 吸收剂量通过治疗后166Ho SPECT/CT上的活度分布估算。
- 代谢反应通过基线与3个月随访之间18F-FDG PET/CT的总病灶糖酵解变化评估。
- 治疗至3个月间的毒性按CTCAE第5版评估,并与肝实质吸收剂量的关系采用线性模型分析。
主要发现
- 肝实质吸收剂量中位数为37 Gy(范围12-55 Gy)。
- 新发CTCAE 3级或以上临床毒性和实验室毒性分别见于8例和7例患者。
- 对于任何临床毒性(每例患者最高等级),CTCAE等级类别每增加一步,肝实质剂量(Gy)的平均差异为5.75(95%CI 1.18-10.32)。
- 患者水平代谢反应:完全缓解1例,部分缓解11例,疾病稳定17例,疾病进展8例。
- 完全或部分缓解患者的平均肿瘤吸收剂量较疾病进展患者高84%(95%CI 20%-180%)。
关键数值与推荐
- 采用100%反应敏感性阈值确定最小平均肿瘤吸收剂量阈值,并评估其对生存的影响。
- 作者主张目标平均肿瘤吸收剂量超过90 Gy且肝实质剂量低于55 Gy。
临床怎么用
- 作者主张未来使用166Ho侦察剂量选择患者并个体化给药活度,目标为平均肿瘤吸收剂量超过90 Gy且肝实质剂量低于55 Gy。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioembolization is a treatment option for colorectal cancer (CRC) patients with inoperable, chemorefractory hepatic metastases. Personalized treatment requires established dose thresholds. Hence, the aim of this study was to explore the relationship between dose and effect (i.e., response and toxicity) in CRC patients treated with 166Ho radioembolization. Methods: CRC patients treated in the HEPAR II and SIM studies were analyzed. Absorbed doses were estimated using the activity distribution on posttreatment 166Ho SPECT/CT. Metabolic response was assessed using the change in total-lesion glycolysis on 18F-FDG PET/CT between baseline and 3-mo follow-up. Toxicity between treatment and 3 mo was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5, and its relationship with parenchyma-absorbed dose was assessed using linear models. The relationship between tumor-absorbed dose and patient- and tumor-level response was analyzed using linear mixed models. Using a threshold of 100% sensitivity for response, the threshold for a minimal mean tumor-absorbed dose was determined and its impact on survival was assessed. Results: Forty patients were included. The median parenchyma-absorbed dose was 37 Gy (range, 12-55 Gy). New CTCAE grade 3 or higher clinical and laboratory toxicity was present in 8 and 7 patients, respectively. For any clinical toxicity (highest grade per patient), the mean difference in parenchymal dose (Gy) per step increase in CTCAE grade category was 5.75 (95% CI, 1.18-10.32). On a patient level, metabolic response was as follows: complete response, n = 1; partial response, n = 11; stable disease, n = 17; and progressive disease, n = 8. The mean tumor-absorbed dose was 84% higher in patients with complete or partial response than in patients with progressive disease (95% CI, 20%-180%). Survival for patients with a mean tumor-absorbed dose of more than 90 Gy was significantly better than for patients with a mean tumor-absorbed dose of less than 90 Gy (hazard ratio, 0.16; 95% CI, 0.06-0.511). Conclusion: A significant dose-response relationship in CRC patients treated with 166Ho radioembolization was established, and a positive association between toxicity and parenchymal dose was found. For future patients, it is advocated to use a 166Ho scout dose to select patients and yo personalize the administered activity, targeting a mean tumor-absorbed dose of more than 90 Gy and a parenchymal dose of less than 55 Gy.
引用
- van Roekel C, Bastiaannet R, Smits MLJ, et al. Dose-Effect Relationships of 166Ho Radioembolization in Colorectal Cancer. J Nucl Med. 2020. PMID: 32591491. doi:10.2967/jnumed.120.243832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。